Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biofrontera (BFRIW) Return on Sales (2020 - 2025)

Biofrontera has reported Return on Sales over the past 6 years, most recently at 0.33% for Q4 2025.

  • Quarterly results put Return on Sales at 0.33% for Q4 2025, up 44.0% from a year ago — trailing twelve months through Dec 2025 was 0.25% (up 22.0% YoY), and the annual figure for FY2025 was 0.25%, up 22.0%.
  • Return on Sales for Q4 2025 was 0.33% at Biofrontera, up from 0.95% in the prior quarter.
  • Over the last five years, Return on Sales for BFRIW hit a ceiling of 0.57% in Q1 2022 and a floor of 3.69% in Q3 2021.
  • Median Return on Sales over the past 5 years was 0.61% (2021), compared with a mean of 0.69%.
  • Biggest five-year swings in Return on Sales: crashed -278bps in 2021 and later surged 310bps in 2022.
  • Biofrontera's Return on Sales stood at 1.58% in 2021, then skyrocketed by 83bps to 0.27% in 2022, then skyrocketed by 221bps to 0.33% in 2023, then crashed by -133bps to 0.11% in 2024, then surged by 397bps to 0.33% in 2025.
  • The last three reported values for Return on Sales were 0.33% (Q4 2025), 0.95% (Q3 2025), and 0.59% (Q2 2025) per Business Quant data.